Aytu BioPharma, Inc. Overview
Pro stress-test →Aytu BioPharma is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics, with its primary products treating attention deficit hyperactivity disorder and other pediatric conditions. The company's business is focused on the launch of EXXUA and its prescription pharmaceutical products sold primarily through third-party wholesalers and pharmacies.
Strategic Profile
Pro stress-test →The company is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease. Key prescription products include Adzenys XR-ODT and Cotempla XR-ODT for ADHD treatment across different age groups.
Competitive Landscape
Pro stress-test →Competitors include Tris Pharma, Novartis, Johnson & Johnson Innovative Medicine, Takeda Pharmaceutical, and Antares Pharma. Aytu competes in the specialty pediatric pharmaceutical space with limited scale compared to major pharma competitors.
Industry Context
Aytu BioPharma, Inc. operates in Specialty Pharmaceuticals.
Key facts
Founded: 2002 · Headquarters: Denver, Colorado · Employees: 127 · Revenue: $62.6M · Market cap: $22.9M